 Manisha Patel
Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsies, Myoclonic | 2 | 2025 | 62 | 1.650 |
Why?
| | Metalloporphyrins | 3 | 2024 | 63 | 1.620 |
Why?
| | Glutathione | 2 | 2024 | 370 | 1.400 |
Why?
| | Oxidative Stress | 5 | 2024 | 1368 | 1.280 |
Why?
| | Epilepsy | 3 | 2026 | 399 | 1.270 |
Why?
| | Mitochondria | 3 | 2025 | 1000 | 1.070 |
Why?
| | Diet, Ketogenic | 1 | 2026 | 39 | 0.910 |
Why?
| | Receptors, GABA | 1 | 2025 | 13 | 0.900 |
Why?
| | Antioxidants | 4 | 2024 | 550 | 0.850 |
Why?
| | Nerve Agents | 1 | 2024 | 7 | 0.810 |
Why?
| | Status Epilepticus | 1 | 2024 | 71 | 0.770 |
Why?
| | Lymphocytes | 1 | 2025 | 378 | 0.760 |
Why?
| | Zebrafish | 2 | 2025 | 536 | 0.720 |
Why?
| | Sirtuin 3 | 1 | 2023 | 60 | 0.720 |
Why?
| | Glucose Metabolism Disorders | 1 | 2021 | 10 | 0.690 |
Why?
| | Drug Resistant Epilepsy | 1 | 2023 | 144 | 0.670 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 43 | 0.640 |
Why?
| | Neuroprotective Agents | 1 | 2021 | 149 | 0.590 |
Why?
| | Astrocytes | 1 | 2021 | 230 | 0.580 |
Why?
| | Neurons | 3 | 2023 | 1672 | 0.550 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 479 | 0.520 |
Why?
| | Glutamate-Cysteine Ligase | 2 | 2024 | 19 | 0.410 |
Why?
| | Rats | 4 | 2024 | 5613 | 0.400 |
Why?
| | Superoxide Dismutase | 3 | 2021 | 308 | 0.350 |
Why?
| | Animals | 8 | 2025 | 38417 | 0.290 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 2542 | 0.240 |
Why?
| | Ketone Bodies | 1 | 2026 | 16 | 0.240 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4605 | 0.220 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2025 | 24 | 0.220 |
Why?
| | Oxazines | 1 | 2025 | 37 | 0.220 |
Why?
| | Isoquinolines | 1 | 2025 | 44 | 0.220 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2025 | 75 | 0.220 |
Why?
| | Cell Respiration | 1 | 2025 | 105 | 0.220 |
Why?
| | Cysteamine | 1 | 2024 | 7 | 0.210 |
Why?
| | Buthionine Sulfoximine | 1 | 2023 | 9 | 0.200 |
Why?
| | Manganese | 1 | 2024 | 59 | 0.200 |
Why?
| | Nerve Degeneration | 1 | 2003 | 49 | 0.200 |
Why?
| | Ligands | 1 | 2025 | 675 | 0.190 |
Why?
| | Reactive Oxygen Species | 2 | 2023 | 617 | 0.190 |
Why?
| | Radiology, Interventional | 1 | 2023 | 49 | 0.190 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2023 | 138 | 0.180 |
Why?
| | Mucormycosis | 1 | 2022 | 18 | 0.180 |
Why?
| | Organophosphates | 1 | 2024 | 179 | 0.180 |
Why?
| | Orbital Diseases | 1 | 2022 | 37 | 0.180 |
Why?
| | Acetylation | 1 | 2023 | 262 | 0.180 |
Why?
| | Oxygen Consumption | 1 | 2025 | 721 | 0.170 |
Why?
| | Mammals | 1 | 2023 | 286 | 0.170 |
Why?
| | Mitochondrial Diseases | 1 | 2002 | 94 | 0.170 |
Why?
| | Fatty Acids | 1 | 2025 | 461 | 0.170 |
Why?
| | Antimalarials | 1 | 2021 | 35 | 0.160 |
Why?
| | Primary Cell Culture | 1 | 2021 | 173 | 0.160 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 125 | 0.160 |
Why?
| | Superoxides | 1 | 2021 | 199 | 0.160 |
Why?
| | Needs Assessment | 1 | 2023 | 409 | 0.160 |
Why?
| | Tissue Distribution | 1 | 2021 | 335 | 0.160 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2023 | 456 | 0.150 |
Why?
| | Blood-Brain Barrier | 1 | 2021 | 167 | 0.150 |
Why?
| | Cell Line | 1 | 2025 | 2832 | 0.150 |
Why?
| | Seizures | 1 | 2023 | 491 | 0.140 |
Why?
| | Pilot Projects | 1 | 2025 | 1912 | 0.140 |
Why?
| | Energy Metabolism | 1 | 2025 | 937 | 0.140 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 649 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2022 | 381 | 0.140 |
Why?
| | Hippocampus | 1 | 2024 | 989 | 0.140 |
Why?
| | Administration, Oral | 1 | 2021 | 874 | 0.130 |
Why?
| | Behavior, Animal | 1 | 2021 | 530 | 0.130 |
Why?
| | Electroencephalography | 1 | 2021 | 570 | 0.130 |
Why?
| | Mice, Knockout | 2 | 2021 | 3153 | 0.130 |
Why?
| | Biomedical Research | 1 | 2023 | 723 | 0.120 |
Why?
| | Motor Activity | 1 | 2021 | 719 | 0.120 |
Why?
| | Male | 5 | 2025 | 73954 | 0.120 |
Why?
| | Mice | 3 | 2023 | 18493 | 0.120 |
Why?
| | Diet | 1 | 2023 | 1284 | 0.110 |
Why?
| | Liver | 1 | 2024 | 1916 | 0.110 |
Why?
| | Pediatrics | 1 | 2023 | 1139 | 0.110 |
Why?
| | Nanoparticles | 1 | 2021 | 524 | 0.100 |
Why?
| | Humans | 8 | 2026 | 147306 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1107 | 0.100 |
Why?
| | Aging | 1 | 2023 | 1992 | 0.090 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 6042 | 0.080 |
Why?
| | Child, Preschool | 1 | 2025 | 12017 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2023 | 11947 | 0.070 |
Why?
| | Child | 2 | 2025 | 22980 | 0.070 |
Why?
| | Female | 3 | 2025 | 80081 | 0.060 |
Why?
| | Adolescent | 1 | 2025 | 22826 | 0.060 |
Why?
| | Culture Media, Serum-Free | 1 | 2003 | 42 | 0.050 |
Why?
| | India | 1 | 2022 | 221 | 0.040 |
Why?
| | Cell Death | 1 | 2003 | 383 | 0.040 |
Why?
| | Antifungal Agents | 1 | 2022 | 153 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2002 | 212 | 0.040 |
Why?
| | Suspensions | 1 | 2021 | 28 | 0.040 |
Why?
| | Solubility | 1 | 2021 | 240 | 0.040 |
Why?
| | Cell Survival | 1 | 2003 | 1111 | 0.040 |
Why?
| | Particle Size | 1 | 2021 | 382 | 0.040 |
Why?
| | Fetus | 1 | 2003 | 805 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2001 | 822 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2002 | 892 | 0.030 |
Why?
| | Estradiol | 1 | 2001 | 515 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2022 | 703 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2022 | 3660 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1720 | 0.020 |
Why?
| | Blood Glucose | 1 | 2022 | 2359 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2496 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 6164 | 0.020 |
Why?
| | Fumarate Hydratase | 1 | 2001 | 3 | 0.010 |
Why?
| | Phenanthridines | 1 | 2001 | 7 | 0.010 |
Why?
| | Tetrazolium Salts | 1 | 2001 | 18 | 0.010 |
Why?
| | Aconitate Hydratase | 1 | 2001 | 14 | 0.010 |
Why?
| | HL-60 Cells | 1 | 2001 | 30 | 0.010 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2001 | 112 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 2001 | 106 | 0.010 |
Why?
| | Epinephrine | 1 | 2001 | 160 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2001 | 762 | 0.010 |
Why?
| | Middle Aged | 1 | 2022 | 36821 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2030 | 0.010 |
Why?
| | Oxygen | 1 | 2001 | 998 | 0.010 |
Why?
| | Protein Binding | 1 | 2001 | 2249 | 0.010 |
Why?
| | Time Factors | 1 | 2001 | 7173 | 0.000 |
Why?
|
|
Patel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|